Formulation Development and Evaluation of Tofacitinib-Loaded PEGylated Liposomal Nanocarriers for Improved Drug Bioavailability
International Journal of Drug Delivery Technology · 30.04.2026 · 16 (23s)
DOI: 10.25258/ijddt.16.23s.82 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 30.04.2026. Verfasst von Santosh Amritlal Raotole und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Tofacitinib, an oral Janus kinase (JAK) inhibitor, demonstrates significant clinical efficacy in autoimmune therapies, yet its therapeutic potential is hindered by a short elimination half-life and poor systemic bioavailability. This study aimed to design, mathematically optimize, and meticulously characterize tofacitinib-loaded PEGylated liposomes to overcome these biopharmaceutical limitations and facilitate sustained systemic delivery.
Methods
The nanocarriers were formulated employing the thin-film hydration technique. A three-factor, three-level BoxBehnken Design (BBD) was utilized to systematically optimize the phospholipid-to-cholesterol ratio, drug-to-lipid mass ratio, and DSPE-PEG2000 molar concentration. The optimized nanocarriers were extensively evaluated for their physicochemical attributes, morphological topology (via TEM), in-vitro release kinetics, and long-term thermodynamic stability.
Results
The optimally formulated PEGylated liposomes (4.2:1 phospholipid-to-cholesterol ratio and 4.8 mol% DSPEPEG2000) exhibited a highly uniform, monodisperse nanoscale geometry with a mean hydrodynamic diameter of 118.25 ± 2.14 nm, a polydispersity index (PDI) of 0.152, and a robust zeta potential of −32.4 mV. The synergistic rigidification by cholesterol and steric stabilization by the PEG corona yielded a maximum entrapment efficiency of 83.15 ± 1.55%. In-vitro dissolution profiling revealed a sustained, biphasic drug release over 72 hours that strictly obeyed Higuchi matrix kinetics, dictated by Fickian diffusion (n = 0.37). Furthermore, the colloidal dispersion demonstrated exceptional structural resilience and payload retention (>81%) over a 90-day stability study at 4 °C.
Conclusion
The successful encapsulation of tofacitinib within thermodynamically stable PEGylated liposomes provides a robust, size-optimized nanocarrier platform capable of prolonged circulation and sustained diffusion. This formulation presents a highly translational strategy for improving the systemic bioavailability and therapeutic index of tofacitinib in clinical settings.
Zitieren
APA
Raotole, S. A., Mishra, S., Nirmala, D., Kaur, E., Addanki, M. M., Sharma, D. K., Bora, A., & Sultan, T. (2026). Formulation Development and Evaluation of Tofacitinib-Loaded PEGylated Liposomal Nanocarriers for Improved Drug Bioavailability. International Journal of Drug Delivery Technology, 16(23s). https://doi.org/10.25258/ijddt.16.23s.82
Vancouver
Raotole SA, Mishra S, Nirmala D, Kaur E, Addanki MM, Sharma DK, et al. Formulation Development and Evaluation of Tofacitinib-Loaded PEGylated Liposomal Nanocarriers for Improved Drug Bioavailability. International Journal of Drug Delivery Technology. 2026;16(23s). doi:10.25258/ijddt.16.23s.82
BibTeX
@article{Raotole2026,
author = {Raotole, Santosh Amritlal and Mishra, Sanjay and Nirmala, Dasari and Kaur, Ekjot and Addanki, Mary Manoranjani and Sharma, Devender Kumar and Bora, Aditya and Sultan, Tahira},
title = {Formulation Development and Evaluation of Tofacitinib-Loaded PEGylated Liposomal Nanocarriers for Improved Drug Bioavailability},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {23s},
doi = {10.25258/ijddt.16.23s.82}
}
EUVIMED